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Abstract 
Introduction: At present, the number of people suffering from diabetes and obesity is 
increasing in China, and also all over the world. Researchers found that decreased 
expression of A-kinase anchoring protein 1 (AKAP1), which was thought to regulate 
the function and structure of mitochondria, might be related to these two diseases. 
However, as far as we know, there is no study about the changes of serum AKAP1 
protein in these two diseases. Hence we conducted this experiment to study the 
relationship between serum levels of AKAP1 with T2DM and obesity.  
Material and methods: There were 261 subjects involved in the experiment, 
including 130 patients with newly diagnosed T2DM and 131 individuals with normal 
glucose tolerance (NGT). They were further divided into four groups as follows. 
Subjects with NGT and normal weight (NW) were assigned to the NGT+NW group, 
those with NGT but with overweight (OW) or obesity (OB) were assigned to the 
NGT+OW/OB group, and so on; the rest were divided into the T2DM+NW group and 
the T2DM+OW/OB group. Serum AKAP1 levels were tested by ELISA method and 
compared by T-test. Linear regression was applied to discuss independent factors of 
AKAP1. Multiple logistic regression was used to analyse the relationship between 
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AKAP1 and the prevalence of T2DM.  
Results: Serum AKAP1 in the NGT+NW group was 1.74 ± 0.42 ng/mL, higher than 
that in the NGT+OW/OB group, at 1.59 ± 0.41 ng/mL (t = 2.114, p = 0.036), and the 
T2DM+OW/OB group, at 1.52 ± 0.36ng/ml (t = 3.219, p = 0.002). A-kinase 
anchoring protein 1 in 130 subjects with T2DM was lower than that in subjects with 
NGT, 1.57 ± 0.35 ng/mL vs. 1.67 ± 0.42 ng/mL, t = 2.036, p = 0.043. Liner regression 
showed that insulin resistance (IR) and body mass index (BMI) were independent 
factors negatively related to AKAP1: β = -0.019 and -0.032, respectively. Compared 
to the highest tertile of AKAP1, the prevalence of T2DM was higher in the other two 
tertiles; OR was 2.207 (1.203, 4.050) and 2.051 (1.121, 3.753), respectively.  
Conclusions: Serum AKAP1 level decreases slightly in patients with T2DM and 
obesity. Subjects with lower leve1s of serum AKAP1 are susceptible to T2DM. 
Key words: A-kinase anchoring protein 1; type 2 diabetes mellitus; obesity 
 
Introduction 
According to the data released by the International Diabetes Federation, there were 
more than 114 million Chinese people suffering from diabetes in 2017 [1]. And in 
2014, the number of obese people in China was 90 million [2]. Diabetes, of which 
T2DM comprises the majority, and obesity have brought a heavy burden to Chinese 
society and families. At present, it is believed that T2DM and obesity are collectively 
caused by many factors, such as environment, diet, exercise, heredity, etc. A growing 
number of studies have confirmed that mitochondrial dysfunction is closely related to 
T2DM and obesity [3]. 
The A-kinase anchored proteins (AKAPs) family is a group of proteins with 
different structures but similar functions. It is named because of its binding property 
with protein kinase A (PKA). A-kinase anchoring protein 1, located in the outer 
membrane of mitochondria (OMM), which plays an important role in maintaining the 
normal metabolism and survival of cells, can maintain the functional activity of 
mitochondrial respiratory chain and regulate the mitochondrial dynamics [4]. Previous 
studies showed that decreased expression of AKAP1 was related to maladjustment of 
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peroxisome proliferator-activated receptor (PPARγ), further damaging the lipolysis 
caused by catecholamine and leading to obesity [5]. The expression of AKAP1 
mRNA decreased in obese subjects [6]. Akap1–/– mice were vulnerable to impaired 
glucose tolerance and insulin resistance [7]. The above studies showed that AKAP1 
might play an important role in the occurrence and development of diabetes and 
obesity. However, few studies are related to serum level of AKAP1 protein in obese 
individuals and patients with diabetes. Hence, we designed this experiment to study 
the changes of serum level of AKAP1 protein in the above population. 
 
Material and methods 
Study subjects 
From October 2019 to February 2020, a total of 261 subjects were involved in the 
study, including 130 patients with newly diagnosed T2DM from the endocrinology 
department of the First Affiliated Hospital of Soochow University, and 131 
individuals with normal glucose tolerance (NGT) from the physical examination 
centre of the hospital. All participants underwent an oral glucose tolerance test 
(OGTT) in which 75 g glucose was dissolved in the appropriate amount of water, and 
all subjects drank it within 5 min. Diabetes was diagnosed as fasting blood glucose 
(FBG) ≥ 7.0 mmol/L and/or 2 h OGTT ≥ 11.1 mmol/L, while NGT was diagnosed as 
FBG < 6.1 mmol/L and 2 h OGTT < 7.8 mmol/L. Height (H) and weight (W) of the 
participates were measured by skilled nurses. Body mass index (BMI) was calculated 
by W/H2: BMI < 25 kg/m2 was defined as normal weight (NW), BMI ≥ 25 kg/m2 and 
< 30 kg/m2 defined as overweight (OW), and BMI ≥ 30 kg/m2 defined as obesity 
(OB). According to the results of OGTT and BMI, the subjects were divided into four 
groups: subjects with NGT and NW were assigned to the NGT+NW group, those with 
NGT but overweight (OW) or obesity (OB) were assigned to the NGT+OW/OB group, 
and so on; the rest were divided into the T2DM+NW group and the T2DM+OW/OB 
group. Exclusion criteria: T1DM; age less than 25 or more than 70 years; BMI ≥ 35 
kg/m2 or < 18.5 kg/m2; Cushing’s syndrome; thyroid disease; acute and chronic heart, 
liver, and kidney disorders; acute complications; pregnancy and lactation; cancer; 
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smoking; and alcohol intake over 140 g per week (male) or 70 g per week (female). In 
addition, patients who had received hypoglycaemic treatment were not enrolled in the 
study, and neither were those who had taken antihypertensive and lipid-lowering 
drugs. However, patients with hypertension or dyslipidaemia but with no history of 
taking medicine were not excluded. The study was approved by the Ethics Committee 
of the hospital; and all the participants were informed and agreed. 
 
Data collection 
Body mass index was obtained as described above, waist circumference (WC) and hip 
circumference (HC) were measured, and the waist/hip ratio (WHR) was calculated as 
WC divided by HC. After sitting for 15 minutes, the blood pressure was measured 
twice on the right upper arm. Systolic blood pressure (SBP) and diastolic blood 
pressure (DBP) were determined by the mean level of the two measurements. Venous 
blood samples were taken after overnight fasting for more than 10 hours. After blood 
centrifugation, serum levels of glutamic-pyruvic transaminase (ALT), creatinine (Cr), 
FBG, total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol 
(HDL-C), and low-density lipoprotein cholesterol (LDL-C) were determined by a 
Hitachi 7600 analyser (Tokyo, Japan). Glycosylated haemoglobin (HbA1c) was tested 
by high-performance liquid chromatography method. Insulin (INS) concentration was 
checked by an automated immunoassay analyser (AIA-2000ST). IR was estimated by 
the following formula: IR = INS * FBG / 22.5. Serum AKAP1 levels were measured 
by using ELISA method (reagents provided by Elabscience Biotechnology, Wuhan, 
China, with a sensitivity of < 0.1 ng/mL. The intra-CV and inter-CV were < 10%). 
 
Data analysis 
Continuous variables were tested by Kolmogorov-Smirnov test to determine whether 
the data conformed to normal distribution, and they were expressed as mean ± S.D. or 
median (P25, P75). T-test or Mann-Whitney U test was used for comparison between 
two groups, while ANOVA or Kruskal-Wallis test was used for comparison between 
multiple groups. Chi-square test was used to compare categorical variables among 
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groups. Pearson correlation was adopted to analyse the correlation between AKAP1 
and other indicators, and stepwise linear regression was adopted to investigate the 
independent risk factors of AKAP1. Before correlation or regression analysis, skew 
distribution data were log-transformed. Multiple logistic regression analysis was used 
to evaluate the association between AKAP1 and the prevalence of T2DM. All 
analyses were performed by SPSS 22.0. p < 0.05 (two sides) was adopted as the level 
of statistical significance. 
 
Results 
The baseline data of the participants 
As shown in Table 1 WC, HC, BMI, SBP, TG, INS, and IR in OW/OB patients were 
higher than those in subjects with NW. Parameters: FBG, HbA1c, INS, and IR in 
patients with T2DM were higher, while Cr was lower than that in those with NGT. 
Waist circumference in the T2DM+NW group was higher than that in the NGT+NW 
group. The lowest WHR was obtained in the NGT+NW group, and the highest in the 
T2DM+OW/OB group. There was no difference in WHR between the other two 
groups. In the T2DM+OW/OB group, TC was higher than in the NGT+NW group, 
LDL-c was higher than in the two NGT groups, and ALT was higher than in the other 
groups. TG in the NGT+OW/OB group was higher than that in the T2DM+NW group, 
while it was lower than that in the T2DM+OW/OB group. High-density lipoprotein 
cholesterol in people with NGT was higher than that in the two T2DM groups, of 
which the T2DM+OW/OB group had the lowest level. Glycated haemoglobin in the 
T2DM+NW group was higher than in the T2DM+OW/OB group. There was no 
significant difference in gender composition, age, and DBP between any two of the 
four groups. 
 
Comparison of serum levels of AKAP1 protein among the groups 
Serum level of AKAP1 protein in the NGT+NW group was 1.74 ± 0.42 ng/mL, higher 
than that in the NGT+NW group (1.59 ± 0.41 ng/mL, t = 2.114, p = 0.036) and the 
T2DM+OW/OB group (1.52 ± 0.36 ng/mL, t = 3.219, p = 0.002), while there was no 
 6 
statistical difference compared with the T2DM+NW group (1.61 ± 0.35 ng/mL, t = 
1.891, p = 0.061). In this experiment, the AKAP1 level in 131 subjects with NGT was 
slightly higher than that in 130 subjects with T2DM, as shown in Figure 1 (1.67 ± 
0.42 ng/mL vs. 1.57 ± 0.35 ng/mL, t = 2.036, p = 0.043). A-kinase anchoring protein 
1 in the two NW groups was higher than in the OW/OB groups (1.68 ± 0.39 ng/mL vs. 
1.55 ± 0.38 ng/mL, t = 2.604, p = 0.010). 
 
Pearson correlation of the relationship between AKAP1 and other variables 
As shown in Table 2, AKAP1 was negatively correlated with BMI, WHR, DBP, and 
TG in the NGT population. In patients with T2DM, AKAP1 was negatively related to 
BMI, SBP, INS, and IR. 
 
Stepwise linear regression studying the independent influencing factors of serum 
AKAP1 level 
From Table 3, it seems that BMI, DBP, and IR were negatively correlated with serum 
AKAP1 level, while HC, surprisingly, might be a positive factor. 
 
Multiple logistic regression about the correlation between serum AKAP1 level and 
the prevalence of T2DM 
According to the serum AKAP1 level, 261 participants were divided into three groups: 
T1 (< 1.44 ng/mL), T2 (1.44–1.69 ng/mL), and T3 (> 1.69 ng/mL). The prevalence of 
T2DM in the T3 group was 37.5%, lower than that in the T1 and T2 groups (55.2% 
and 57.0%), respectively (Fig. 2, chi-square test). 
Multiple logistic regression showed that the risk of T2DM of T2 and T1 was 
significantly higher when compared to the T3 group, even after adjusting some factors 
including BMI and TG, as shown in model 1–3 in Table 4. However, after the 
adjustment for HDL-C, the prevalence of T2DM between T2 and T3 became less 
statistically significant, while the prevalence in T1 was still higher than in T3 (model 
4 in Table 4). When further taking HC into consideration, we found that there was no 
significant difference of the prevalence among the three groups (model 5 in Table 4). 
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Discussion 
Adenosine triphosphate (ATP) is mainly produced by mitochondria. Mitochondrial 
dysfunction affects the ATP/ADP ratio and insulin secretion [8]. Moreover, 
mitochondria are also the main source of reactive oxygen species (ROS). Their 
dysfunction produces excessive ROS, which aggravates inflammatory response and 
insulin resistance [9]. It is believed that mitochondrial disorder is closely related to 
T2DM. 
  AKAP1 mediates PKA and protein tyrosine phosphatase-D1 targeting OMM, 
which phosphorylates important components of the oxidative respiratory chain, such 
as NDUFS4 and cytochrome c oxidase, further regulating oxidative respiration and 
ATP production [10, 11]. In addition, PKA phosphorylates and inactivates dynamic 
related protein 1 (Drp1), thus inhibiting mitochondrial fission [12]. It indicates that 
AKAP1 is critical in maintaining the function and structure of mitochondria. What is 
more, down-regulation of AKAP1 expression leads to mitochondrial dysfunction and 
increased ROS production, suggesting that AKAP1 also plays an important role in 
limiting the abnormal increase of ROS [13].  
   A previous study showed that AKAP1 deficiency would aggravate the abnormal 
glucose tolerance and insulin resistance, and promote liver gluconeogenesis and 
steatosis in high-fat fed mice. Further observation under an electron microscope 
revealed the notably abnormal mitochondrial structures in these mice. The 
mitochondria were found to be obviously swelling, the electron density became lower, 
and the cristae became fewer and shorter. In view of the above, AKAP1 deficiency 
accounting for mitochondrial dysfunction was thought to promote the development of 
diabetes [7]. In our experiment, the serum level of AKAP1 protein was negatively 
correlated with IR and slightly decreased in people with T2DM, which seemed to be 
consistent with the above study. Some researchers once divided obese people into a 
high-IR group and low-IR group, according to their levels of IR, and found no 
significant difference of AKAP1 mRNA expression between the two groups [5]. We 
did not find any significant difference in serum AKAP1 levels in OW/OB subjects 
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with NGT and with T2DM in our experiment, although the levels of IR in these two 
groups were marked distinctively. However, further studies are needed to confirm the 
relationship between AKAP1 and diabetes. 
  It is thought that AKAP1 plays a role in fat and energy metabolism in a variety of 
ways: Primarily, AKAP1 may mediate PKA phosphorylation of proteins involved in 
lipid metabolism, including hormone sensitive lipase (HSL) and perilipin [14]. 
Secondly, PKA regulatory subunit IIB (prkar2b) plays an important central role in 
regulating energy consumption and glycolipid metabolism, and it is thought that 
AKAP1 mediated subcellular localisation of prkar2b is necessary for the effective 
transduction of signals regulating lipolysis [15]. Furthermore, AKAP1 may be a target 
gene of PPARγ, which is an important regulator of fat formation. PPARγ mutant 
causes the decrease of HSL activity and the impairment of lipolysis mediated by 
β-adrenergic, which may be related to AKAP1/PKA dysfunction [5]. Finally, AKAP1 
can anchor protein phosphatase 1 on the lipid droplets of fat cells and mediate its role 
in fat metabolism [16]. 
Researchers found that AKAP1 mRNA decreased in adipose tissue of obese 
subjects [5, 6]. A-kinase anchoring protein 1 deficiency would promote fat deposition 
and fat cell hypertrophy in adipose tissue and aggravate obesity symptoms [7]. It 
seems that AKAP1 might be a negative factor in fat and energy metabolism. However, 
in another experiment, AKAP1–/– mice were found to have lower weight than 
wild-type counterparts [17]. Our results showed that there was a downward trend of 
serum AKAP1 level in the OW/OB population, and AKAP1 was negatively correlated 
with BMI. Moreover, AKAP1 was negatively related with TG in the NGT population, 
suggesting that AKAP1 might be involved in the regulation of fat metabolism. 
A-kinase anchoring protein 1 had been confirmed before our study to regulate the 
cardiovascular system, including inhibiting cardiomyocyte hypertrophy, improving 
myocardial ischaemia and protecting the function of endothelial cell (EC) [18]. 
A-kinase anchoring protein 1 deficiency selectively damaged endothelium-dependent 
vasodilation, leading to an increase in blood pressure [19, 20]. It also seemed that 
there might be a negative trend between AKAP1 and blood pressure in our study. It is 
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generally believed that AKAP1 deficiency leads to the decrease of protein kinase B 
(PKB, Akt) phosphorylation, which may play a regulatory role towards EC through 
endothelial NO synthase (eNOS)-NO pathway [19, 20]. However, it has been 
confirmed that PKA can directly regulate eNOS [21]. Moreover, Akt-mammalian 
target of rapamycin (mTOR) signalling pathway is important for EC function, while 
mTOR has been proven to be the downstream target of AKAP1 in cancer [22]. It 
needs to be confirmed whether there are other potential mechanisms in the regulation 
of AKAP1 on blood vessels. 
In addition, AKAP1 may control cholesterol transport by regulating the activity 
of steroid acute regulatory factors through a post-transcriptional mechanism [23, 24] 
and possibly affecting the structure of mitochondrial-associated endoplasmic 
reticulum membrane [23, 25]. However, no evidence in our study and others showed 
the relationship between AKAP1 and cholesterol. 
 
Conclusions 
In this paper, we found that AKAP1, which was negatively correlated with IR and 
BMI, showed a slight downward trend in patients with newly diagnosed T2DM. 
However, it is only a cross-sectional experiment with a small sample size. Previous 
studies have shown that rosiglitazone could increase the expression of AKAP1 mRNA 
[5], and metformin could affect the structure and function of mitochondria [26, 27]. 
Further studies are required, to investigate the effect of hypoglycaemic drugs on 
AKAP1, as well the variety of AKAP1 with prolonged course of disease. 
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Table 1. Measured data of participants 
Variables NGT+NW NGT+OW/OB T2DM+NW T2DM+OW/OB p 
N (M/F) 68 (36/32) 63 (34/29) 66 (36/30) 64 (35/29) 0.889 
Age 
(year) 
45.26 ± 
12.33 
47.06 ± 11.37 46.36 ± 11.59 43.53 ± 10.71 0.334 
WC [cm] 81.00 ± 
5.20 
90.33 ± 7.67a 84.70 ± 
6.48a,b 
96.42 ± 8.18a,b,c < 
0.001 
HC [cm] 94.85 ± 
4.71 
100.51 ± 6.35a 93.55 ± 6.21b 101.73 ± 8.26a,c < 
0.001 
WHR 0.85 ± 0.05 0.90 ± 0.04a 0.91 ± 0.07a 0.95 ± 0.06a,b,c < 
0.001 
BMI 
[kg/m2] 
23.09 ± 
1.62 
26.95 ± 1.80a 22.37 ± 
1.74a,b 
27.82 ± 2.44 a,b,c < 
0.001 
SBP 
[mmHg] 
123.63 ± 
14.08 
128.71 ± 
14.15a 
123.70 ± 
12.59b 
130.00 ± 12.89a,c 0.008 
DBP 
[mmHg] 
83.99 ± 
9.14 
86.91 ± 9.41 83.64 ± 7.24 86.98 ± 9.90 0.048 
ALT 
[U/L] 
20.71 ± 
14.93 
23.43 ± 13.41 24.39 ± 14.37 34.63 ± 18.64a,b,c < 
0.001 
Cr 
[umol/L] 
58.98 ± 
12.99 
61.95 ± 12.04 48.91 ± 11.72 
a,b 
51.57 ± 13.50a,b < 
0.001 
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FBG 
[mmol/L] 
4.93 (4.58, 
5.24) 
5.04 (4.73, 
5.38) 
8.02 (6.42, 
11.31)a,b 
9.09 (7.64, 
10.59)a,b 
< 
0.001 
TC 
[mmol/L] 
4.78 ± 0.89 5.00 ± 0.78 4.94 ± 0.98 5.21 ± 1.08a 0.063 
TG 
[mmol/L] 
0.97 (0.78, 
1.36) 
1.32 (0.91, 
1.87)a 
1.19 (0.89, 
1.52)a,b 
1.98 (1.33, 
2.71)a,b,c 
< 
0.001 
HDL-C 
[mmol/L] 
1.34 (1.18, 
1.58) 
1.32 (1.11, 
1.46) 
1.05 (0.92, 
1.17)a,b 
0.91 (0.78, 
1.03)a,b,c 
< 
0.001 
LDL-C 
[mmol/L] 
2.93 ± 0.80 3.10 ± 0.75 3.21 ± 0.85 3.40 ± 0.95a,b 0.012 
HbA1c 
(%) 
5.38 ± 0.25 5.41 ± 0.32 12.08 ± 
2.05a,b 
10.91 ± 1.72a,b,c < 
0.001 
INS 
[mIU/L] 
5.85 (3.98, 
7.47) 
7.65 (5.26, 
9.12)a 
10.85 (6.92, 
13.03)a,b 
13.54 (10.08, 
18.56)a,b,c 
< 
0.001 
IR 1.25 (0.88, 
1.68) 
1.63 (1.11, 
2.05)a 
3.78 (2.48, 
5.72)a,b 
5.31 (3.77, 
7.57)a,b,c 
< 
0.001 
AKAP1 
[ng/mL] 
1.74 ± 0.42 1.59 ± 0.41a 1.61 ± 0.35 1.52 ± 0.36a 0.011 
Data are mean ± SD or median (P25, P75). avs. NGT+NW group, p < 0.05; bvs. 
NGT+OW/OB group, p < 0.05; cvs. T2DM+NW, p < 0.05 
 
NGT — normal glucose tolerance; NW — normal weight; OW — overweight; OB — obesity; 
T2DM — type 2 diabetes mellitus; WC — waist circumference; HC — hip circumference; 
WHR — waist–hip ratio; BMI — body mass index; SBP — systolic blood pressure; DBP — 
diastolic blood pressure ALT — glutamic-pyruvic transaminase; Cr — creatinine; FBG — 
fasting blood glucose; TC — total cholesterol; TG — triglyceride; HDL-C — high-density 
lipoprotein cholesterol; LDL-C — low-density lipoprotein cholesterol; HbA1c — glycosylated 
haemoglobin; INS — insulin; IR — insulin resistance; A-kinase anchoring protein 1; SD — 
standard deviation 
 
Table 2. Correlation between serum A-kinase anchoring protein 1 (AKAP1) level and 
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BMI — body mass index; WC — waist circumference; HC — hip circumference; WHR — 
waist–hip ratio; BMI — body mass index; SBP — systolic blood pressure; DBP — diastolic 
blood pressure ALT — glutamic-pyruvic transaminase; Cr — creatinine; FBG — fasting 
blood glucose; TC — total cholesterol; TG — triglyceride; HDL-C — high-density 
lipoprotein cholesterol; LDL-C — low-density lipoprotein cholesterol; HbA1c — glycosylated 
haemoglobin; INS — insulin; IR — insulin resistance 
 
 
Table 3. The independent influencing factors of A-kinase anchoring protein 1 
other variables in patients with normal glucose tolerance (NGT) and patients with 
type 2 diabetes mellitus 
AKAP1 
NGT T2DM 
r p r p 
Sex 0.061 0.487 0.106 0.232 
Age –0.062 0.482 0.038 0.667 
BMI –0.182 < 0.05 –0.224 < 0.05 
WC –0.170 0.053 –0.129 0.144 
HC –0.053 0.550 –0.065 0.460 
WHR –0.203 < 0.05 –0.117 0.184 
SBP –0.163 0.062 –0.175 < 0.05 
DBP –0.201 < 0.05 –0.110 0.211 
ALT –0.095 0.283 –0.116 0.224 
Cr –0.091 0.305 –0.122 0.167 
FBG –0.035 0.689 –0.060 0.501 
TC –0.099 0.361 –0.024 0.786 
TG –0.192 <0.05 –0.103 0.243 
HDL-C 0.042 0.632 0.079 0.343 
LDL-C –0.047 0.593 –0.021 0.811 
HbA1c –0.085 0.337 0.095 0.281 
INS –0.163 0.063 –0.188 < 0.05 
IR –0.140 0.112 –0.202 < 0.05 
 15 
(AKAP1) 
Variabl
es 
Unstandardised 
coefficients t p 
95% CI for β 
β Std. Error Lower Upper 
Constant 2.004 0.357 5.616 < 0.01 1.3002 2.707 
HC 0.010 0.005 2.206 < 0.05 0.001 0.019 
BMI –0.032 0.011 –2.842 < 0.01 –0.055 –0.010 
DBP –0.006 0.003 –2.173 < 0.05 –0.011 –0.001 
IR –0.019 0.009 –.2.237 < 0.05 –0.037 –0.002 
R Square of this model is 0.089. 
CI — confidence interval; HC — hip circumference; BMI — body mass index; DBP — 
diastolic blood; IR — insulin resistance 
 
 
Table 4. Correlation between A-kinase anchoring protein 1 (AKAP1) and prevalence 
of type 3 diabetes mellitus (T2DM)  
 T3 T2 T1 
Referenc
e 
OR (95% CI) P OR (95% CI) p 
Model 
1 
1 2.207 (1.203,4.050) < 0.05 2.051 (1.121,3.753) < 0.05 
Model 
2 
1 2.413 (1.121,5.196) < 0.05 2.196 (1.018,4.738) < 0.05 
Model 
3 
1 2.429 (1.033,5.949) < 0.05 2.963 (1.197,7.332) < 0.05 
Model 
4 
1 2.085 (0.780,5.576) 0.143 3.104 (1.129,8.529) < 0.05 
Model 
5 
1 1.655 (0.601,4.559) 0.330 2.625 (0.931,7.398) 0.068 
Model 1: crude; Model 2: adjusted for sex, age, ALT, Cr; model 3: adjusted for model 2 + 
WC, BMI, SBP, DBP, TC, TG, LDL-c; model 4: adjusted for model 3 + HDL-C; model 5: 
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adjusted for model 4 + HC; OR — odds ratio; CI — confidence interval 
 
 
Figure 1. Serum A-kinase anchoring protein 1 (AKAP1) in people with normal 
glucose tolerance (NGT) vs. in people with type 2 diabetes mellitus (T2DM): 1.67 ± 
0.42 vs. 1.57 ± 0.35 ng/mL (p = 0.043) 
 
 
Figure 2. The prevalence of type 2 diabetes mellitus (T2DM) in T1, T2, and T3 
groups is, respectively, 55.2%, 57.0%, and 37.5%. *represents vs. T3 groups, p < 0.05, 
chi-square test 
 
